Answers are grounded in this paper and cite their sources.
CHIPS was highly predictive of EFS, identifying a subset (with CHIPS 2 or 3) that comprises 27% of intermediate-risk patients who have a 4-year EFS of <80% and who may benefit from early therapeutic augmentation. Furthermore, CHIPS identified higher risk patients who were not identified by early PET or CT response. CHIPS is a robust and inexpensive approach to predicting risk in patients with intermediate-risk HL that may improve ability to tailor therapy to risk factors known at diagnosis.
No takes yet. Share an insight, caveat, or question.
Schwartz et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: